Cargando…
Letter: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9)
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean Diabetes Association
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943272/ https://www.ncbi.nlm.nih.gov/pubmed/31902148 http://dx.doi.org/10.4093/dmj.2019.0205 |
| _version_ | 1783484854614097920 |
|---|---|
| author | Sohn, Tae Seo |
| author_facet | Sohn, Tae Seo |
| author_sort | Sohn, Tae Seo |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6943272 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Korean Diabetes Association |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-69432722020-01-09 Letter: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9) Sohn, Tae Seo Diabetes Metab J Letter Korean Diabetes Association 2019-12 2019-12-26 /pmc/articles/PMC6943272/ /pubmed/31902148 http://dx.doi.org/10.4093/dmj.2019.0205 Text en Copyright © 2019 Korean Diabetes Association http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letter Sohn, Tae Seo Letter: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9) |
| title | Letter: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9) |
| title_full | Letter: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9) |
| title_fullStr | Letter: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9) |
| title_full_unstemmed | Letter: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9) |
| title_short | Letter: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9) |
| title_sort | letter: comparison of the efficacy of rosuvastatin monotherapy 20 mg with rosuvastatin 5 mg and ezetimibe 10 mg combination therapy on lipid parameters in patients with type 2 diabetes mellitus (diabetes metab j 2019;43:582–9) |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943272/ https://www.ncbi.nlm.nih.gov/pubmed/31902148 http://dx.doi.org/10.4093/dmj.2019.0205 |
| work_keys_str_mv | AT sohntaeseo lettercomparisonoftheefficacyofrosuvastatinmonotherapy20mgwithrosuvastatin5mgandezetimibe10mgcombinationtherapyonlipidparametersinpatientswithtype2diabetesmellitusdiabetesmetabj2019435829 |